Vaccine Against Type Ro Dosage Efficacy Features Adverse Reaction Contraindications

ute
Bacillus live attenuated (from ID 0.05ml at birth 86% against meningitis and erythemainduration impaired immunity may
Calmette- Guerin Mycobacterium bovis) disseminated TB (not TB infxn) ulceration scar cause disseminated infxn
Hepatitis B recombinant plasmid of IM 3 doses: 80-100% birth dose: mild
HBSAg inserted in  0 mo  high risk countries
Saccharomyces  1-2 mos  + HBSAg mom add
cervisiae  6-8 mos HBig
Highest titer = 4 mos spacing
bet 2nd and 3rd dose

Diptheria chemically killed IM 3 doses 95-97% combined with tetanus and erythema and swelling
Clostridium diphtheria  4- 8 wks apart (w/ booster) pertussis
 start 6 wks
4th dose = 6 mos-1 yr after 3rd
dose
5th dose = 4-6 y/o

Td = every 10 yrs
Tdap = at 7 y/o

Lapsed:
 7 yrs (0,1 6 mos) Tdap
 10 yrs Tdap in one of 3
doses then Td
Pertussis whole cell IM 3 doses DTwP combined with tetanus and erythema and swelling Encephalopathy
- formally inactivated  4 - 8wks apart = 70-90%, diptheria  > DTwP
Bordetella pertussis  start 6 wks) Precaution:
4th dose = at least 1 y/o DtaP Acute encephalopathy  neurologic
Acellular 5th dose = 4-6 y/o = 80-85%  10:1M condition
- subunits in inactivated  family hx of sz
pertussis toxin booster Tdap  severe local rxn
 10 y/o
 catch up booster
  pregnant
Tetanus whole cell IM 3 doses combined with pertussis and - erythema and swelling hx of severe local rxn
- formally inactivated  4 - 8wks apart diptheria - Arthus reaction
Clostridium tetani  start 6 wks) - Guillain Barre
4th dose = at least 1 y/o Syndrome
Acellular 5th dose = 4-6 y/o
- subunits in inactivated
pertussis toxin booster Tdap
 10 years old
 catch up booster
 pregnant

Adult dose of Td
 every 10 yrs
Hemophilus Hib capsular IM 3 doses 95-100% Monovalent
Influeza Type B polysaccharide  4 - 8wks apart combines with DPT and/or
conjugated to carrier  start 6 wks Hepa B
protein 4th dose = at least 1 yr

Lapsed:
 7-12 mos = 2 doses
then 1 dose after 1 yr
 12-14 mos = 2 doses (4-
8 wks apart)
 15-59 mos = single
dose
Poliovirus Trivalent OPV IM 3 doses IPV
- live attenuated or  4 - 8wks apart  protects from vaccine
- containing serotypes PO  start 6 wks associated paralytic
1,2,3 4th dose = at least 1 yr poliomyelitis (VACC)
 VACC, Vaccine derived
Trivalent IPV polioviruses (NDRV)
- inactivated polio virus
Rotavirus Monovalent / PO 4 - 8wks apart starting 6 wks prevent severe rotavirus - hospitalized children
Pentavalent live  Pentavalent = 3 p.o, diarrhea - children with acute or
reassortment  Monovalent = 2 p.o. moderate gastroentiritis

Max. age:
 Pentavalent = 32wks
 Monovalent = 24wks

1st dose:
 Pentavalent = before
14 wks
 Monovalent= 20 wks
 to prevent
intussuception
Pneumococcal PCV IM 10 and 13 valent PCV PCV protects from:
- 10 valent, 13 valent - 3 doses  invasive dse
conjugate capsular  4 - 8wks apart  otitis media
polysaccharide of S.  start 6 wks  nasopharyngeal
pneumonia carriage
Lapsed:
PPV  7-12 mos = 2 doses
- 23 valent then 1 dose after 1 yr
pneumococcal capsular  12-14 mos = 2 doses (4-
polysaccharide 8 wks apart)
 15-59 mos = single
dose

PPV = at 2 y/o
Measles Live attenuated (from SQ 1st dose = 9-12 mos 95% - febrile sz (MMRV) immunosuppression
chick embryo) 2nd dose = after 1 year (failure - transient
to respond to initial dose lymphadenopathy
(MMR)
3rd dose = 4-6 y/o (MMR)
 Lapses:
 2 doses 4 wks apart if
MMR
 12 wks if MMRV
Mumps Live attenuated SQ 1st dose = after 1 year (MMR) 90-98% MMRV not for > 13 years old - parotitis immunosuppression
2nd dose = 4-6 y/o (MMR) - orchitis
Used for: - febrile sz (MMRV)
Lapses:  vaccine outbreaks in - aseptic meningitis
 2 doses 4 wks apart if school (primary
MMR vaccine failure)
 12 wks if MMRV  adolescent (waning
immunity)
Rubella Live attenuated SQ 1st dose = after 1 year (MMR) 90% MMRV not for > 13 years old - fever - immunosuppression
2nd dose = 4-6 y/o (MMR) - lymphadenopathy - pregnancy
- arthralgia
Lapses:
 2 doses 4 wks apart if
MMR
 12 wks if MMRV
Varicella Live attenuated SQ 1st dose = after 1 year (MMR) 70-90% MMRV not for > 13 years old macupapular rash - immunosuppression
2nd dose = 4-6 y/o (MMR) - pregnancy
Breakthrough infxn = 42 days
Lapses: 12wks after vaccination

Influenzae Trivalent/Quadrivalent SQ Minimum age: 6 mos 70-90% Waning of vaccine induced GBS - immunosuppression
inactivated or  0.25 ml = 6-35 mos antibody - egg allergy
IM  0.5 ml = > 3 y/o

6month to 8 y/o
 2 doses (if first time)
then 1 dose thereafter
Human Papiloma Bivalent/ Quadrivalent/ IM Bivalent = 16,18) 67-89% (for - pain Anaphylaxis
Virus Recombinant Quadrivalent = 6,11,16 & 18 7.5yrs) - swelling
 9- 14 y/o = 2 doses 6 mos apart
15-45 y/o = 0,1,6

Hepatitis A Inactivated IM 1st dose = 12 mos 94-100%

Live attenuated 2nd dose = 6-12 mos

Adult dose = 18 y/o

Typhoid Capsular polysaccharide IM Single dose = at 2 years 70-80% headache fever
(Vi CPS) of S. typhi revaccination = after 2-3 years
Japanese B Inactivated mouse SQ Minimum age: 9mos 96% after 2 Waning of vaccine induced Hypersensitivity rxn hypersensitivity rxn to
Encephalitis brain derived  9 mos to 17 y/o = 1st doses antibody thimerosal
dose then 2nd dose 1-2
yrs after
 18 y/o = single dose

Meningococcal MPSV4 (SQ) IM MCV4 Used in outbreaks - headache

- Polysaccharide or  1st dose = 9 mos - body malaise
SQ  2nd dose = 18 mos
MCV4 (IM)
- Quadrivalent against MPSV4 = 2 y/o
serogroups A,C,Y,W-
135
Rabies Inactivated IM IM = 0.5ml None
or ID = 0.1ml
ID
Pre-exposure: 3 doses
 Day 0,7,21 or 28
 if completed, will only
be given 2 doses (Day
0,3 if exposed)

Post-Exposure Prophylaxis
(PEP): 5 doses
 Day 0,3,7,14,28
  2-1-1 = Day 0,7,28
Dengue Inactivated SQ for 9 to 45 y/o
 3 doses
 month 1,6,12